STORM Therapeutics' First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference
/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting...
United States San Diego United Kingdom Jerry Mcmahon Konstantinos Tzelepis Cambridge Stem Cell Institute
Source: prnewswire.com